Pure Global
NCT05927155

Effects of Acute Long-acting Bronchodilation on Oxygenation and Peripheral Ventilation in COPD

Comparison of Bronchodilation and Oxygenation Patterns Induced by Long-acting β2-agonists and Muscarinic Antagonists in Chronic Obstructive Pulmonary Disease (COPD)
Erasme University Hospital·Phase 3·ClinicalTrials.gov·drugCompleted
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Pulmonary Disease, Chronic Obstructive
Drug/Device/Intervention
LABA
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Erasme University Hospital
Location
Brussels, Belgium
Timeline & enrollment
Phase
Phase 3
Start date
Jun 15, 2021
End date
Mar 30, 2022
Enrollment
30 participants
Primary outcome

Tissue oxygenation (TcO2) change from baseline,Tissue oxygenation (TcO2) change from baseline

Summary

The goal of this clinical trial was to compare the action of long-acting ß2-agonists
 (LABA-olodaterol) and muscarinic antagonists (LAMA-tiotropium) on tissue oxygenation in COPD
 considering their impact on proximal and peripheral ventilation and, eventually, on lung
 capillary volume. The hypothesis was that LABA would have a more peripheral effect than LAMA
 (due to the opposite gradient of their receptors) and better peripheral ventilation would
 result in a greater oxygenation.
 
 Before and after LABA (visit 1) and LAMA (visit 2) inhalation, COPD participants were asked
 to perform single-breath washout and forced oscillation tests, double diffusion technique and
 spirometry, while transcutaneous oxygenation was continuously recorded.

ICD-10 classifications
Chronic obstructive pulmonary disease, unspecifiedOther chronic obstructive pulmonary diseaseOther specified chronic obstructive pulmonary diseaseChronic obstructive pulmonary disease with acute exacerbation, unspecifiedChronic obstructive pulmonary disease with acute lower respiratory infection
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05927155
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05927155 through Pure Global AI's free database. This Phase 3 trial is sponsored by Erasme University Hospital and is currently Completed. The study focuses on Pulmonary Disease, Chronic Obstructive. Target enrollment is 30 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.